Practical considerations in transitioning to hybrid or decentralised clinical trials
An ICON Whitepaper endorsed by the PCMG
Insight from clinical and data operations, mobile health sensor management and regulatory experts provides a framework of practical advice on how to get it right first time and avoid increased patient and site burden for optimal outcomes.
Biopharma perspective: The promise of decentralised models and diversity in clinical trials
ICON invited senior biopharma executives to discuss how decentralised and hybrid clinical trial models can provide increased resilience and how their respective organisations are currently or likely to address diversity and inclusion in clinical trials going forward. Our summary report outlines how these executives see the opportunity in the developments of 2020, paving the way for continuous improvements into the future.